A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma.

This document provides information about a clinical trial currently recruiting participants at Fudan University in China. The trial, NCT06445803, is studying the use of anti-CD19/CD22 CAR T cells (KQ-2002) in adults with recurrent or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma. The trial involves screening, cell collection, lymphodepleting chemotherapy, and CAR T cell infusion. Patients will be followed for two years after the cell infusion to monitor for potential long-term side effects. The study is in Phase 1 and is non-randomized. The trial is expected to be completed in December 2026. [Extracted from the article]